Overcoming metabolic syndrome in severe obesity: Adiponectin as a marker of insulin sensitivity and HDL-cholesterol improvements after gastric bypass;Reversão da síndrome metabólica na obesidade mórbida: Adiponectina como um marcador da sensibilização à insulina e do aumento do HDL-colesterol após o bypass gástrico

Arquivos Brasileiros de Endocrinologia e Metabologia

Volumn 53, Issue 2, 2009, Pages 293-300

  Geloneze, Bruno ^a,b   Pereira, Juliano Alves ^a   Pareja, José Carlos ^a   de Oliveira Lima, Marcelo Miranda ^a   Lazarin, Mary Aparecida Carvalho Tavares ^a   de Souza, Iara Chaves Pereira ^a   Tambascia, Marcos Antonio ^a,b   Chaim, Elinton ^a   Muscelli, Elza ^a,c  

^a UNIVERSITY OF CAMPINAS   (Brazil)

^b Instituto de Investigac ão em Imunologia Instituto Nacional de Ciência e Tecnologia INCT   (Brazil)

^c UNIVERSITY OF PISA   (Italy)

Author keywords

Adiponectin; Gastric bypass; Glucose clamp technique; HDL cholesterol; Insulin resistance; Obesity; Weight loss

Indexed keywords

EID: 67649414452     PISSN: 00042730     EISSN: 16779487     Source Type: Journal    
DOI: 10.1590/S0004-27302009000200022     Document Type: Article

References (40)

1. DeFronzo RA, Ferrannini E. Insulin resistance: a multifaceted syndrome responsible for NIDDM, obesity, hypertension, dyslipidemia and atherosclerotic disease. Diabetes Care. 1991;14(3):173-94.
2. Ferrannini E, Natali A, Bell P, Cavallo-Perin P, Lalic N, Mingrone G. Insulin resistance and hypersecretion in obesity. J Clin Invest. 1997;100(5):1166-73.
3. WHO Consultation. Definition, diagnosis and classification of diabetes mellitus and its complications. Part 1: diagnosis and classification of diabetes mellitus. Geneva: World Health Organization, 1999. Report no 99.2. Available from: http://whqlibdoc.who.int/hq/1999/WHO_NCD_NCS_99.2.pdf
4. Alberti KG, Zimmet P, Shaw J. Metabolic syndrome - a new world-wide definition. A Consensus Statement from the International Diabetes Federation. Diabet Med. 2006;23(5):469-80.
5. Berg AH, Combs TP, Scherer PE. ACRP30/adiponectin: an adipokine regulating glucose and lipid metabolism. Trends Endocrinol Metab. 2002;13(2):84-9.
6. Weyer C, Funahashi T, Tanaka S, Hotta K, Matsuzawa Y, Pratley RE, et al. Hypoadiponectinemia in obesity and type 2 diabetes: close association with insulin resistance and hyperinsulinemia. J Clin Endocrinol Metab. 2001;86(5):1930-5.
7. Szmitko PE, Teoh H, Stewart DJ, Verma S. Adiponectin and cardiovascular disease: state of the art? Am J Physiol Heart Circ Physiol. 2007;292(4):H1655-63.
8. Kazumi T, Kawagushi A, Sakai K, Hirano T, Yshino G. Young men with high-normal blood pressure have lower serum adiponectin, smaller LDL size, and higher elevated heart rate than those with optimal blood pressure. Diabetes Care. 2002;25(6):971-6.
9. Pellme F, Smith U, Funahashi T, Matsuzawa Y, Brekke H, Wiklund O, et al. Circulating adiponectin levels are reduced in nonobese but insulin-resistant first-degree relatives of type 2 diabetic patients. Diabetes. 2003;52(5):1182-6.
10. Ouchi N, Kihara S, Arita Y, Maeda K, Kuriyama H, Okamoto Y, et al. Novel modulator for endothelial adhesion molecules: adipocyte-derived plasma protein adiponectin. Circulation. 1999;100(25):2473-6.
11. Okamoto Y, Arita Y, Nishida M, Muraguchi M, Ouchi N, Takahashi M, et al. An adipocyte-derived plasma protein, adiponectin, adheres to injured vascular walls. Horm Metab Res. 2000;32(2):47-50.
12. Hotta K, Funahashi T, Bodkin NL, Ortmeyer HK, Arita Y, Hansen BC, et al. Circulating concentrations of the adipocyte protein adiponectin are decreased in parallel with reduced insulin sensitivity during the progression to type 2 diabetes in rhesus monkeys. Diabetes. 2001;50(5):1126-33.
13. Lara-Castro C, Fu Y, Chung BH, Garvey WT. Adiponectin and the metabolic syndrome: mechanisms mediating risk for metabolic and cardiovascular disease. Curr Opin Lipidol. 2007;18(3):263-70.
14. von Eynatten M, Hamann A, Twardella D, Nawroth PP, Brenner H, Rothenbacher D. Relationship of adiponectin with markers of systemic inflammation, atherogenic dyslipidemia, and heart failure in patients with coronary heart disease. Clin Chem. 2006;52(5):853-9.
15. Cnop M, Havel PJ, Utzschneider KM, Carr DB, Sinha MK, Boyko EJ, et al. Relationship of adiponectin to body fat distribution, insulin sensitivity and plasma lipoproteins: evidence for independent roles of age and sex. Diabetologia. 2003;46(4):459-69.
16. Baratta R, Amato S, Degano C, Farina MG, Patanè G, Vigneri R, et al. Adiponectin relationship with lipid metabolism is independent of body fat mass: evidence from both cross-sectional and intervention studies. J Clin Endocrinol Metab. 2004;89(6):2665-71.
17. Neumeier M, Sigruener A, Eggenhofer E, Weigert J, Weiss TS, Schaeffler A, et al. High molecular weight adiponectin reduces apolipoprotein B and E release in human hepatocytes. Biochem Biophys Res Commun. 2007;352(2):543-8.
18. Vergès B, Petit JM, Duvillard L, Dautin G, Florentin E, Galland F, et al. Adiponectin is an important determinant of apoA-I catabolism. Arterioscler Thromb Vasc Biol. 2006;26(6):1364-9.
19. Pereira JA, Lazarin MA, Pareja JC, de Souza A, Muscelli E. Insulin resistance in nondiabetic morbidly obese patients: effect of bariatric surgery. Obes Res. 2003;11(12):1495-501.
20. Geloneze B, Tambascia MA, Pareja JC, Repetto EM, Magna LA. The insulin tolerance test in severely obese patients undergoing bariatric surgery. Obes Res. 2001;9(12):763-9.
21. de Carvalho CP, Marin DM, de Souza AL, Pareja JC, Chaim EA, de Barros Mazon S, et al. GLP-1 and Adiponectin: effect of weight loss after dietary restriction and gastric bypass in morbidly obese patients with normal and abnormal glucose metabolism. Ob Surg. 2009;19-313-20.
22. Swarbrick MM, Havel PJ. Physiological, pharmacological, and nutritional regulation of circulating adiponectin concentrations in humans. Metab Syndr Relat Disord. 2008;6(2):87-102.
23. Calvani M, Scarfone A, Granato L, Mora EV, Nanni G, Castagneto M, et al. Restoration of adiponectin pulsatility in severely obese subjects after weight loss. Diabetes. 2004;53(4):939-47.
24. Guldstrand M, Ahréen B, Adamsom U. Improved β-cell function after standardized weight reduction in severely obese subjects. Am J Physiol Endocrinol Metab. 2003;284(3):E557-65.
25. Kotidis EV, Koliakos GG, Baltzopoulos VG, Ioannidis KN, Yovos JG, Papavramidis ST. Serum ghrelin, leptin and adiponectin levels before and after weight loss: comparison of three methods of treatment: a prospective study. Obes Surg. 2006;16(11):1425-32.
26. American Diabetes Association. Report of expert Committee on Diagnosis and Classification of Diabetes Mellitus. Diabetes Care.1997;20(7):1183-97.
27. Capella RF, Capella JF. Reducing early technical complications in gastric bypass surgery. Obes Surg. 1997;7(2):149-56.
28. DeFronzo RA, Tobin JD, Andres R. Glucose clamp technique: a method for quantifying insulin secretion and resistance. Am J Physiol. 1979;237(3):E214-23.
29. Geloneze B, Pareja JC. Does bariatric surgery the metabolic syndrome? Arq Bras Endocrinol Metabol. 2006;50(2):400-7.
30. Swarbrick MM, Austrheim-Smith IT, Stanhope KL, Van Loan MD, Ali MR, Wolfe BM, et al. Circulating concentrations of high-molecular-weight adiponectin are increased following Roux-en-Y gastric bypass surgery. Diabetologia. 2006;49(11):2552-8.
31. Polak J, Kovacova Z, Jacek M, Klimcakova E, Kovacikova M, Vitkova M, et al. An increase in plasma adiponectin multimeric complexes follows hypocaloric diet-induced weight loss in obese and overweight pre-menopausal women. Clin Sci (Lond). 2007;112(11):557-65.
32. Yamamoto Y, Hirose H, Saito I, Tomita M, Taniyama M, Matsubara K, et al. Correlation of the adipocyte-derived protein adiponectin with insulin resistance index and serum high-density lipoprotein-cholesterol, independent of body mass index, in the Japanese population. Clin Sci. 2002;103(2):137-42.
33. Combs TP, Pajvani UB, Berg AH, Lin Y, Jelicks LA, Laplante M et al. A transgenic mouse with a deletion in the collagenous domain of adiponectin displays elevated circulating adiponectin and improved insulin sensitivity. Endocrinology. 2004;145(1):367-83.
34. Shibata R, Ouchi N, Kihara S, Sato K, Funahashi T, Walsh K. Adiponectin stimulates angiogenesis in response to tissue ischemia through stimulation of AMP-activated protein kinase signaling. J Biol Chem. 2004;279(27):28670-4.
35. Westphal S, Borucki K, Taneva E, Makarova R, Luley C. Adipokines and treatment with niacin. Metabolism. 2006;55(10):1283-5.
36. Nakamura T, Kodama Y, Takano H, Umetani K, Fujioka D, Saito Y, et al. Increase in circulating levels of adiponectin after treatment with statin and fibrate in patients with coronary artery disease and hyperlipidemia. Atherosclerosis. 2007;193(2):449-51.
37. Hibuse T, Fujita K, Nishizawa H, Adler Y, Motro M, Kihara S, et al. Effects of peroxisome proliferator-activated receptor ligands, bezafibrate and fenofibrate, on adiponectin level. Arterioscler Thromb Vasc Biol. 2007;27(3):635-41.
38. Bahia L, Aguiar LG, Villela N, Bottino D, Godoy-Matos AF, Geloneze B, et al. Adiponectin is associated with improvement of endothelial function after rosiglitazone treatment in nondiabetic individuals with metabolic syndrome. Atherosclerosis. 2007;195(1):138-46.
39. Maruyama C, Imamura K, Teramoto T. Assessment of LDL particle size by triglyceride/HDL-cholesterol ratio in non-diabetic, healthy subjects without prominent hyperlipidemia. J Atheroscler Thromb. 2003;10(3):186-91.
40. Barter PJ, Puranik R, Rye KA. New insights into the role of HDL as an anti-inflammatory agent in the prevention of cardiovascular disease. Curr Cardiol Rep. 2007;9(6):493-8.